Locations
San Francisco, CA, USA · South San Francisco, CA, USA
industry
Biotech · Biotechnology · Clinical Research · Drug Discovery · Healthcare · Health Care · Medical · Oncology · Science and Engineering
Size
11 - 50 employees
Stage
Other
founded in
2018
Electra Therapeutics focuses on developing therapies that target the Signal Regulatory Protein (SIRP) family of receptors on immune cells. The company's portfolio of SIRP-directed antibodies is designed to address the underlying pathology across a range of diseases by selectively depleting pathological immune cells. The lead product candidate, ELA026, is a monoclonal antibody currently in pivotal clinical development for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition. Electra Therapeutics is also advancing a second program, ELA822, for use in immunology and inflammation conditions.
Something looks off?